# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Kevin Caliendo maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $8.5 to $9.
2025 GuidanceLifeStance is providing the following outlook for 2025:The Company is reiterating full year revenue of $1.40 billi...
UBS analyst Kevin Caliendo upgrades LifeStance Health Gr (NASDAQ:LFST) from Neutral to Buy and announces $8.5 price target.
LifeStance Health Gr (NASDAQ:LFST) sees Q2 sales of $332.000 million-$352.000 million vs $352.76 million analyst estimate.